Viral Meningitis-Associated Hospitalizations in the United States, 1988–1999Khetsuriani N.a · Quiroz E.S.a,b · Holman R.C.c · Anderson L.J.a
aRespiratory and Enteric Viruses Branch, Division of Viral and Rickettsial Diseases (DVRD), Centers for Disease Control and Prevention (CDC), bEpidemic Intelligence Service, Epidemiology Program Office, CDC, and cOffice of the Director, DVRD, CDC, Atlanta, Ga., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
We used the National Hospital Discharge Survey and the Nationwide Inpatient Sample of the Health Care Cost and Utilization Project to estimate disease burden associated with viral meningitis hospitalizations in the United States. During 1988–1999, viral meningitis accounted for an estimated 434,000 hospitalizations (annual average, 36,000; average annual hospitalization rate, 14/100,000), and 2.1 million hospital days (annual average, 175,000). The estimated mean charge for viral meningitis-associated hospitalization during 1993–1997 varied between USD 6,562 and 8,313, resulting in annual estimated hospitalization costs between USD 234 and 310 million and a total estimated cost of nearly USD 1.3 billion for the 5-year period. In summary, viral meningitis remains an important cause of morbidity and financial burden and merits efforts to improve diagnostic, treatment, and prevention options.
© 2003 S. Karger AG, Basel
Rotbart HA: Meningitis and encephalitis; in Rotbart HA (ed). Human Enterovirus Infections. Washington, ASM Press, 1995, pp 271–289.
- Rubeiz H, Roos R: Viral meningitis and encephalitis. Semin Neurol 1992;12:165–177.
Romero JR: Enteroviruses: Diagnosis, screening and surveillance. Infect Med 1999;16 (suppl D):11–20.
Ahmed A, Brito F, Goto C, et al: Clinical utility of the polymerase chain reaction for diagnosis of enteroviral meningitis in infancy. Pediatrics 1997;131:393–397.
- Hamilton MS, Jackson MA, Abel D:. Clinical utility of polymerase chain reaction testing for enteroviral meningitis. Pediatric Infect Dis J 1999:18:533–537.
- Tanel RE, Shaw-Yi K, Niemiec TM, et al: Prospective comparison of culture vs genome detection for diagnosis of enteroviral meningitis in childhood. Arch Pediatr Adolesc Med 1996;150:919–924.
Romero JR: Pleconaril: A novel antipicornaviral drug. Expert Opin Invest Drugs 2001;10:369–379.
Parasuraman TV, Deverka PA, Toscani MR: Estimating the economic impact of viral meningitis in the United States. Infect Med 2000;17:417–427.
Parasuraman TV, Deverka PA, Toscani MR: Identification of resource use and associated costs for viral meningitis. Manag Care 2000;9:41–46.
- Centers for Disease Control and Prevention: Summary of notifiable diseases, United States, 1994. MMWR Morb Mortal Wkly Rep 1994;43:1–80.
Popovic JR: 1999 National Hospital Discharge Survey: Annual summary with detailed diagnoses and procedure data. Vital Health Stat Ser 13 2001;151:1–206.
National Center for Health Statistics: National Hospital Discharge Survey: Multi-Year Data Tape Information, 1979–99. Hyattsville, National Center for Health Statistics, 2001.
Healthcare Cost and Utilization Project: Nationwide Inpatient Sample (NIS), Release 6, 1997. Rockville, Agency for Healthcare Research and Quality, 1999.
US Public Health Service and Health Care Financing Administration: International Classification of Diseases, Ninth Revision, Clinical Modification, ed 6. (CD-ROM). Hyattsville, Centers for Disease Control and Prevention, 1998.
Graves EJ, Kozak LJ: National Hospital Discharge Survey: Annual summary, 1996. Hyattsville, National Center for Health Statistics. Vital Health Stat Ser 13, 1999, No 140.
Kozak LJ: Underreporting of race in the National Hospital Discharge Survey. Advance Data from Vital and Health Statistics. Hyattsville, National Center for Health Statistics, 1995, No 265.
US Bureau of the Census: Intercensal Estimates of the Population by Age, Sex, and Race: 1970–1999. Washington, US Bureau of the Census, 2001.
US Department of Health and Human Services: Detail data 1979–1999. Public Use Data Tape Documentation. Natality. Hyattsville, Centers for Disease Control and Prevention, National Center for Health Statistics, 2001.
Shah BV, Barnell BG, Bieler GS: SUDAAN User’s Manual, Release 7.0. Research Triangle Park, Research Triangle Institute, 1996.
Sirken MG, Shimizu BI, French DK, Brock DB: Manual on Standards and Procedures for Reviewing Statistical Reports. Hyattsville, Centers for Disease Control and Prevention, National Center for Health Statistics, 1992.
Gillum BS, Graves EJ, Jean L: Trends in hospital utilization. United States, 1988–1992. Vital Health Stat Ser 13 1996;124:1–71.
- Centers for Disease Control and Prevention: Enterovirus surveillance – United States, 1990. MMWR Morb Mortal Wkly Rep 1990;39:788–789.
Centers for Disease Control and Prevention: Nonpolio enterovirus surveillance – United States, 1993–1996. MMWR Morb Mortal Wkly Rep 1997;46:748–750.
- Centers For Disease Control and Prevention: Enterovirus surveillance – United States, 1997–1999. MMWR Morb Mortal Wkly Rep 2000;49:913–916.
- Centers for Disease Control and Prevention: Enterovirus surveillance – United States, 1989. MMWR Morb Mortal Wkly Rep 1989;38:563.
- Nicolosi A, Hauser WA, Beghi E, Kurland L: Epidemiology of central nervous system infections in Olmsted Country, Minnesota, 1950–1981. J Infect Dis 1986;154:399–408.
- Elmore JG, Horwits RI, Quagliarello VJL: Acute meningitis with a negative Gram’s stain: Clinical and management outcomes in 171 episodes. Am J Med 1996;100:78–84.
- Centers for Disease Control and Prevention: Outbreak of aseptic meningitis – Whiteside county, Illinois, 1995. MMWR Morb Mortal Wkly Rep 1997;46:221–224.
- Rice SK, Heinl RE, Thornton LI, Opal SM: Clinical characteristics, management strategies, and cost implications of a statewide outbreak of enterovirus meningitis. Clin Infect Dis 1995;20:931–937.
- Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Broome CV, Wenger JD: Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993;269:221–226.
- Centers for Disease Control and Prevention: Progress toward elimination of Haemophilus influenzae type B invasive disease among infants and children – United States, 1998–2000. MMWR Morb Mortal Wkly Rep 2002;51:234–237.
- Centers for Disease Control and Prevention: Progress toward elimination of Haemophilus influenzae type B disease among infants and children – United States, 1987–1997. MMWR Morb Mortal Wkly Rep 1998;47:993–998.
Powderly WG: Recent advances in the management of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22(suppl 2):S119–S123.
Apisarnthanarak A, Powderly WG: Treatment of acute cryptococcal disease. Expert Opin Pharmacother 2001;2:1259–1268.
- Marshall GS, Hauck MA, Buck G, Rabalais GP: Potential cost savings through rapid diagnosis of enteroviral meningitis. Pediatr Infect Dis J 1997;16:1086–1087.
- Wall TC, Fargason CA, Johnson VA: Comparison of inpatient charges between academic and not academic services in a children’s hospital. Pediatrics 1997;99:175–179.
- Ramers C, Billman G, Hartin M, Ho S, Sawyer MH: Impact of a diagnostic cerebrospinal fluid enterovirus polymerase chain reaction test on patient management. JAMA 2000;283:2680–2685.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.